C18 dihydro Ceramide-d3 is intended for use as an internal standard for the quantification of C18 dihydro ceramide (d18:0/18:0) by GC- or LC-MS. C18 dihydro Ceramide is a bioactive sphingolipid and precursor in the de novo synthesis of C18 ceramide (d18:1/18:0) that lacks the 4,5-trans double bond.[1] Increased C18 dihydro ceramide lipid levels lead to increased triacylglycerol storage and autophagosome accumulation as well as upregulation of the fibrosis markers α-SMA and FGF2 in Chang and LX-2 liver cells. C18 dihydro Ceramide is elevated in the plasma of pre-diabetics up to 9 years prior to the onset of type 2 diabetes.[2] It is also elevated in the skin of patients with lesional atopic dermatitis.[3]
Reference:
[1].Lee, A.Y., Lee, J.W., Kim, J.-E., et al.Dihydroceramide is a key metabolite that regulates autophagy and promotes fibrosis in hepatic steatosis modelBiochem. Biophys. Res. Commun.494(3-4)460-469(2017)
[2].Wigger, L., Cruciani-Guglielmacci, C., Nicolas, A., et al.Plasma dihydroceramides are diabetes susceptibility biomarker candidates in mice and humansCell Rep.18(9)2269-2279(2017)
[3.]Joo, J.-M., Hwang, J.-H., Bae, S., et al.Relationship of ceramide-, and free fatty acid-cholesterol ratios in the stratum corneum with skin barrier function of normal, atopic dermatitis lesional and non-lesional skinsJ. Dermatol. Sci.77(1)71-74(2015)